Citation Impact
Citing Papers
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
2009 StandoutNobel
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Cancer statistics, 2022
2022 Standout
Signalling and survival pathways in multiple myeloma
2006
Cancer statistics, 2023
2023 Standout
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Cancer Statistics, 2021
2021 Standout
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
Reduced maternal expression of adrenomedullin disrupts fertility, placentation, and fetal growth in mice
2006 StandoutNobel
The mechanisms of Hedgehog signalling and its roles in development and disease
2013 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
Targeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
2020
The FGF family: biology, pathophysiology and therapy
2009 Standout
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
SNIPERs—Hijacking IAP activity to induce protein degradation
2019
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma
2010
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Targeted therapy in rare cancers—adopting the orphans
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia
2002
Lgr5-Expressing Cells Are Sufficient and Necessary for Postnatal Mammary Gland Organogenesis
2013
mTOR Activation Induces Tumor Suppressors that Inhibit Leukemogenesis and Deplete Hematopoietic Stem Cells after Pten Deletion
2010
Wnt Proteins Are Self-Renewal Factors for Mammary Stem Cells and Promote Their Long-Term Expansion in Culture
2010
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
2010
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
2009
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
2011
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Wnt/β-Catenin Signaling and Disease
2012 Standout
T-Cell and NK-Cell Posttransplantation Lymphoproliferative Disorders
2007
Ba/F3 cells and their use in kinase drug discovery
2006
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
2006
Immunophenotype of neoplastic plasma cells in AL amyloidosis
2009
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Genetic events in the pathogenesis of multiple myeloma
2007
Systemic amyloidosis
2015 Standout
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
2006
Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi
2006
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Signalling Pathways Implicated in Early Mammary Gland Morphogenesis and Breast Cancer
2006
Targeting mutant p53 for efficient cancer therapy
2017
Hedgehog beyond medulloblastoma and basal cell carcinoma
2010
CASK Functions as a Mg2+-Independent Neurexin Kinase
2008 StandoutNobel
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
2014
The PI3K Pathway in Human Disease
2017 Standout
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults
2011
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
2005
Cancer-related inflammation
2008 StandoutNature
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Sexual dimorphism in glioma glycolysis underlies sex differences in survival
2017
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
2006
Modeling Development and Disease with Organoids
2016 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Developmental signaling pathways in cancer stem cells of solid tumors
2012
Animal models of implantation
2004
Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation
2005
β-Arrestin–Mediated Localization of Smoothened to the Primary Cilium
2008 StandoutScienceNobel
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Multiple Myeloma
2010
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
2005
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
2008
Cancer Genome Landscapes
2013 StandoutScience
How I treat multiple myeloma in younger patients
2009
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
2007
mTOR: a pharmacologic target for autophagy regulation
2015 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor
2010
Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
2009
Somatic hypermutation of the B cell receptor genesB29(Igβ, CD79b) andmb1(Igα, CD79a)
2003
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor
2007
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
The Hedgehog Signaling Pathway in Cancer
2006
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemia
2015
AID to overcome the limitations of genomic information
2005 StandoutNobel
Works of Hong Chang being referenced
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway
2015
p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
2009
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma
2004
p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines
1995
Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53)Deletion in Chronic Lymphocytic Leukemia
2009
Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma
2007
Basigin expression and hormonal regulation in mouse uterus during the peri‐implantation period
2002
Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland
2006
Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation
2006
p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide
2012
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
2004
Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
2014
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma
2010
Analysis of PTEN deletions and mutations in multiple myeloma
2005
Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma
2007
PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53
2015
Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy
2019
Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization
1999
Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis
2011
Multiple myeloma patients with CKS1B gene amplification have a shorter progression‐free survival post‐autologous stem cell transplantation
2006
Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia
2003
Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant
2005
Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen
2009
Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation
2005
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
2006
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
2009
Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
2007
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
2004
T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders
2005
Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance
2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
2005
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006
p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation
2004
Ptch1is required locally for mammary gland morphogenesis and systemically for ductal elongation
2009